Evidence map›Paper›PMID 40827317›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Anna Lavrova, Nha Trang Thu Pham, Cynthia J Vernon, Jonathan Graff-Radford, Bradley F Boeve, David S Knopman, Kejal Kantarci, Clifford R Jack, Aivi T Nguyen, Reichard R Ross and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anna LavrovaDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Nha Trang Thu PhamDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Cynthia J VernonDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Kejal KantarciDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Aivi T NguyenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Reichard R RossDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Mayo Clinic, Jacksonville, Florida, USA.
Val LoweDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Funding

Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Alzheimer's Disease Research Center P30-AG62677Alzheimer's Disease Research Center P50-AG01654Mayo Clinic Study of Aging U01-AG06786NIA NIH HHS R01-AG37491NIA NIH HHS R01-NS112153NIA NIH HHS R37 AG011378
6 · The paper itself

Abstract

introductionPrimary age-related tauopathy (PART) is defined by neurofibrillary tangles (NFTs) with absent-minimal amyloid beta (Aβ) plaques. Currently, definitive diagnosis of PART occurs with autopsy. This study investigated whether [

methodsWe performed a retrospective cross-sectional study of 88 individuals (mean age 85.6) with autopsy-confirmed PART (Braak I to IV; Thal phases 0 to 2) who underwent ante mortem FDG-PET. Visual ratings and standardized uptake value ratios (SUVRs) were analyzed in medial and lateral temporal lobes, inferior temporal pole, precuneus, and posterior cingulate regions.

resultsMedial temporal hypometabolism was observed in PART, in the presence of co-pathologies. Argyrophilic grain disease and TAR DNA-binding protein 43 were associated with greater hypometabolism (p < 0.01). Lewy body disease affected parietal regions. DISCUSSION: FDG-PET reveals that PART-related hypometabolism occurs when co-pathologies are present, but PART alone appears to have minimal effect on medial temporal lobe hypometabolism. HIGHLIGHTS: FDG-PET hypometabolism worsens with Braak NFT stage. FDG-PET detects mild lateral temporal lobe hypometabolism in PART alone. PART alone has a minimal effect on medial temporal lobe hypometabolism. Medial temporal hypometabolism is worse in PART with TDP-43 and especially AGD. The presence of LBD contributes to parietal hypometabolism on FGD-PET in PART.

Indexed as

BrainFluorodeoxyglucose F18Positron-Emission TomographyTauopathiesAgedAged, 80 and overCross-Sectional StudiesFemaleHumansMaleNeurofibrillary TanglesRadiopharmaceuticalsRetrospective StudiesFluorodeoxyglucose F18Radiopharmaceuticals18F‐fluorodeoxyglucose positron emission tomographyargyrophilic grain diseaseFDG‐PETprimary age‐related tauopathyTAR DNA‐binding protein 43

Identifiers

PMID40827317
PMCPMC12361867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.